XML 26 R34.htm IDEA: XBRL DOCUMENT v3.19.3
SEGMENT INFORMATION (Tables)
9 Months Ended
Sep. 30, 2019
Segment Reporting [Abstract]  
Information About Reportable Segments and Reconciliation of Segment Net Sales to Consolidated Net Sales and Segment Pre-Tax Income to Consolidated Pre-Tax Income
The table below presents information about Edwards Lifesciences' reportable segments (in millions):
 
Three Months Ended   
September 30,
 
Nine Months Ended   
September 30,
 
2019
 
2018
 
2019
 
2018
Segment Net Sales
 

 
 

 
 

 
 

United States
$
647.8

 
$
518.5

 
$
1,835.5

 
$
1,510.2

Europe
219.8

 
191.6

 
684.3

 
608.1

Japan
110.0

 
95.4

 
322.9

 
288.4

Rest of World
112.0

 
96.8

 
316.5

 
290.2

Total segment net sales
$
1,089.6

 
$
902.3

 
$
3,159.2

 
$
2,696.9

Segment Operating Income
 

 
 

 
 

 
 

United States
$
447.4

 
$
353.0

 
$
1,258.3

 
$
1,010.5

Europe
111.5

 
90.9

 
353.2

 
295.6

Japan
70.7

 
55.0

 
202.8

 
171.8

Rest of World
36.7

 
28.3

 
99.8

 
89.6

Total segment operating income
$
666.3

 
$
527.2

 
$
1,914.1

 
$
1,567.5


The table below presents reconciliations of segment net sales to consolidated net sales and segment operating income to consolidated pre-tax income (in millions):
 
Three Months Ended   
September 30,
 
Nine Months Ended   
September 30,
 
2019
 
2018
 
2019
 
2018
Net Sales Reconciliation
 

 
 

 
 

 
 

Segment net sales
$
1,089.6

 
$
902.3

 
$
3,159.2

 
$
2,696.9

Foreign currency
4.4

 
4.3

 
14.7

 
48.2

Consolidated net sales
$
1,094.0

 
$
906.6

 
$
3,173.9

 
$
2,745.1

Pre-tax Income Reconciliation
 

 
 

 
 

 
 

Segment operating income
$
666.3

 
$
527.2

 
$
1,914.1

 
$
1,567.5

Unallocated amounts:
 

 
 

 
 

 
 

Corporate items
(384.2
)
 
(281.0
)
 
(1,073.1
)
 
(792.0
)
Special charge (Note 4)

 

 
(24.0
)
 

Intellectual property litigation expenses
(7.9
)
 
(7.9
)
 
(19.5
)
 
(19.1
)
Change in fair value of contingent consideration liabilities, net
2.3

 
6.4

 
(12.4
)
 
(8.3
)
Foreign currency
17.8

 
4.2

 
50.9

 
5.4

Consolidated operating income
294.3

 
248.9

 
836.0

 
753.5

Non-operating income
7.4

 
(0.2
)
 
15.0

 
9.7

Consolidated pre-tax income
$
301.7

 
$
248.7

 
$
851.0

 
$
763.2


Enterprise-Wide Information
Enterprise-wide information is based on actual foreign exchange rates used in the Company's consolidated condensed financial statements.
 
Three Months Ended   
September 30,
 
Nine Months Ended   
September 30,
 
2019
 
2018
 
2019
 
2018
 
(in millions)
 
 
 
 
Net Sales by Geographic Area
 

 
 

 
 

 
 

United States
$
647.8

 
$
518.7

 
$
1,835.5

 
$
1,510.3

Europe
222.6

 
201.3

 
699.0

 
659.3

Japan
112.9

 
94.2

 
324.4

 
289.5

Rest of World
110.7

 
92.4

 
315.0

 
286.0

 
$
1,094.0

 
$
906.6

 
$
3,173.9

 
$
2,745.1

Net Sales by Major Product and Service Area
 

 
 

 
 

 
 

Transcatheter Aortic Valve Replacement
$
700.0

 
$
557.1

 
$
1,975.4

 
$
1,692.2

Transcatheter Mitral and Tricuspid Therapies
9.7

 
0.7

 
21.0

 
2.1

Surgical Structural Heart
204.1

 
184.6

 
636.6

 
554.4

Critical Care
180.2

 
164.2

 
540.9

 
496.4

 
$
1,094.0

 
$
906.6

 
$
3,173.9

 
$
2,745.1


 
September 30, 2019
 
December 31, 2018
 
(in millions)
Long-lived Tangible Assets by Geographic Area
 

 
 

United States
$
791.5

 
$
642.1

Europe
73.7

 
36.6

Japan
23.1

 
6.7

Rest of World
258.7

 
214.4

 
$
1,147.0

 
$
899.8